Literature DB >> 2257863

The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon.

H Mönig1, M Böhm, E E Ohnhaus, W Kirch.   

Abstract

We have studied the pharmacokinetics of phenprocoumon with and without co-administration of frusemide and probenecid in two groups of 17 healthy volunteers. Frusemide 40 mg b.i.d. for 7 days did not interact with phenprocoumon to a significant extent. Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.h.ml-1, and a reduction in the fraction of the dose excreted by the kidneys. The data are consistent with inhibition of the glucuronidation of phenprocoumon by probenecid. Its accelerated elimination may be a consequence of the increased formation of hydroxylated metabolites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2257863     DOI: 10.1007/bf00315107

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Probenecid and hepatic transport of 3-H-ouabain in rats.

Authors:  R Erttmann; K H Damm
Journal:  Arch Int Pharmacodyn Ther       Date:  1974-10

2.  Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide.

Authors:  J A Boutin; J Thomassin; G Siest; A M Batt
Journal:  Pharmacol Res Commun       Date:  1984-03

3.  Blood-brain and CSF barriers to penicillin and related organic acids.

Authors:  R A Fishman
Journal:  Arch Neurol       Date:  1966-08

4.  Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine.

Authors:  T Meinertz; H J Gilfrich; U Groth; H G Jonen; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

5.  Probenecid-clofibrate interaction.

Authors:  J R Veenendaal; P M Brooks; P J Meffin
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

6.  The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon.

Authors:  F Andreasen; S Husted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-09

7.  The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon.

Authors:  N R Kitteringham; L Büstgens; E Brundert; S Mineshita; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac.

Authors:  P C Smith; P N Langendijk; J A Bosso; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

9.  Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation.

Authors:  D R Abernethy; D J Greenblatt; B Ameer; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1985-08       Impact factor: 4.030

10.  Probenecid: an unexplained effect on cephalosporin pharmacology.

Authors:  P G Welling; S Dean; A Selen; M J Kendall; R Wise
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

View more
  1 in total

1.  Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal.

Authors:  J I Macdonald; S M Wallace; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.